Cancer Treatment Today

Adjuvant chemotherapy is the standard of care for patients with stage II or III NSCLC based on the results from large randomizedtrials and meta-analyses. HOWEVER, IT IS NOT ROUTINE FOR STAGE IB LUNG CANCER AND IS USED IN STAGES ii-iii. The FDA has granted breakthrough therapy designation to osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

Osimertininb is in a clinical trial ADAURA for early-stage lung cancer as adjuvvant therapy. The full results are expected in mid-2020. The first interim analysis was presented at ASCO 2020 meeting and showed that adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated nonsmall cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated.

Yi-LOng Wu et al,ADAURA: Phase III, Double-blind, RandomizedStudy of Osimertinib Versus Placebo in EGFRMutation-positive Early-stage NSCLC AfterComplete Surgical Resection. Clinical  Lung  Cancer,Vol. 19, No. 4, e533-36ª2018

NCCN Non-small cell lung cancer NSCL-4 2020